Drug Profile
Buprenorphine extended-release - Indivior
Alternative Names: Atrigel buprenorphine; BUP-XR-Indivior; Depot buprenorphine; RBP-6000; SUBLOCADE; Sublocade; SUBUTEX; Subutex® prolonged releaseLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Reckitt Benckiser Pharmaceuticals
- Developer Indivior
- Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor agonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Opioid-related disorders
Most Recent Events
- 31 Dec 2021 Launched for Opioid-related disorders in Israel (SC) before 2021
- 31 Dec 2021 Registered for Opioid-related disorders in Denmark, New Zealand, Italy, Germany, Norway (SC) before 2021
- 14 Apr 2021 Virginia Commonwealth University in collaboration with Indivior terminates a phase IIIb VOTIVE trial in Opioid-related-disorders, in USA (NCT03818399)